Using molecular beacons for cancer imaging and treatment
Using molecular beacons for cancer imaging and treatment
复制标题
DOI：
10.2741/2420
复制
发表时间：
2007-05-01
影响因子：
3.1
通讯作者：
Zheng, Gang
中科院分区：
文献类型：
--
作者：
Stefflova, Klara;Chen, Juan;Zheng, Gang
分子信标基本上是照亮特定细胞靶或具有相似特征的细胞的所有探针。在这篇综述中，我们重点介绍了那些使用近红外荧光成像（NIRF-I）来识别癌症特有的细胞和代谢标志物的分子信标。它们采用各种递送和活化途径，选择性或特异性地靶向增殖和永生的癌细胞。这些信标可以用于与治疗分开的成像步骤，或者它们可以将这两个步骤紧密连接到单个过程中。与NIRF-I相匹配的癌症疗法是光动力疗法（PDT），其使用某些卟啉染料的光触发光毒性特性。在信标恢复的荧光的引导下，PDT激光可以聚焦在受影响的部位，利用同一信标增强的光活性杀死癌细胞。反之亦然--从裂解的信标中恢复的荧光可以用作信标自身治疗成功的指示，对PDT后凋亡细胞成像。
Molecular beacons are essentially all probes that illuminate particular cellular target or cells with similar characteristics. In this review we focus on those molecular beacons that use near-infrared fluorescence imaging (NIRF-I) to identify the unique cellular and metabolic markers characteristic of cancer. They employ various delivery and activation pathways, selectively or specifically targeting proliferating and immortal cancer cells. These beacons can either be used in an imaging step separate from therapy or they can intimately connect these two steps into a single process. Matching cancer therapy to NIRF-I is photodynamic therapy (PDT) that uses the light-triggered phototoxic properties of some porphyrin-based dyes. Guided by beacon's restored fluorescence, the PDT laser could be focused on affected sites, killing the cancer cells using the enhanced photoactivity of the same beacon. Or vice versa-the restored fluorescence from the cleaved beacon could be used as an indication of the beacon's own therapeutic success, imaging the post-PDT apoptotic cells.